Evolution of Theranostic Nanoparticles Through the Lens of Patents DOI Creative Commons
Danielle Teixeira Freire, Júlio Abreu Miranda, Matheus Cardoso de Oliveira

и другие.

Journal of Nanotheranostics, Год журнала: 2025, Номер 6(2), С. 11 - 11

Опубликована: Апрель 9, 2025

Theranostic nanoparticles integrate diagnostic and therapeutic potential, representing a promising approach in precision medicine. Accordingly, numerous inventions have been patented to protect novel formulations methods. This review examines the evolution of theranostic nanoparticles, focusing on organic nanosystems, particularly polymeric lipid assess their development, technological advances, patentability. A scoping was conducted following Preferred Reporting Items for Systematic reviews Meta-Analyses (PRISMA) guidelines World Intellectual Property Organization (WIPO) European Patent Office (EPO) database. The search included patents filed within last ten years (2014–2024) that specifically claimed and/or hybrid nanoparticles. Data extraction focused nanoparticle composition, synthesis methods, functionalization strategies, applications. identified 130 patents, which 13 met inclusion criteria. These were primarily by inventors from United States, Canada, Great Britain, Italy, China. Polymeric frequently engineered targeted drug delivery imaging, utilizing hyperbranched polyesters, sulfated polymers, or chitosan-based formulations. Lipid often hybridized with inorganic nanomaterials magnetic nanostructures enhance potential. While most detailed methods physicochemical characterizations, only few provided comprehensive preclinical validation, limiting demonstrated efficacy. analysis recent highlights significant advances design application However, notable gap remains validating these nanosystems clinical translation. Future efforts should emphasize robust data, including vitro vivo assessments, patent quality applicability substantiate capabilities.

Язык: Английский

Evolution of Theranostic Nanoparticles Through the Lens of Patents DOI Creative Commons
Danielle Teixeira Freire, Júlio Abreu Miranda, Matheus Cardoso de Oliveira

и другие.

Journal of Nanotheranostics, Год журнала: 2025, Номер 6(2), С. 11 - 11

Опубликована: Апрель 9, 2025

Theranostic nanoparticles integrate diagnostic and therapeutic potential, representing a promising approach in precision medicine. Accordingly, numerous inventions have been patented to protect novel formulations methods. This review examines the evolution of theranostic nanoparticles, focusing on organic nanosystems, particularly polymeric lipid assess their development, technological advances, patentability. A scoping was conducted following Preferred Reporting Items for Systematic reviews Meta-Analyses (PRISMA) guidelines World Intellectual Property Organization (WIPO) European Patent Office (EPO) database. The search included patents filed within last ten years (2014–2024) that specifically claimed and/or hybrid nanoparticles. Data extraction focused nanoparticle composition, synthesis methods, functionalization strategies, applications. identified 130 patents, which 13 met inclusion criteria. These were primarily by inventors from United States, Canada, Great Britain, Italy, China. Polymeric frequently engineered targeted drug delivery imaging, utilizing hyperbranched polyesters, sulfated polymers, or chitosan-based formulations. Lipid often hybridized with inorganic nanomaterials magnetic nanostructures enhance potential. While most detailed methods physicochemical characterizations, only few provided comprehensive preclinical validation, limiting demonstrated efficacy. analysis recent highlights significant advances design application However, notable gap remains validating these nanosystems clinical translation. Future efforts should emphasize robust data, including vitro vivo assessments, patent quality applicability substantiate capabilities.

Язык: Английский

Процитировано

0